2 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
Schedule of Components of Income Tax Provision
2023 | 2022 | |||||||
Deferred tax: | ||||||||
Deferred | (1,829,030) | (1,784,880) | ||||||
Change in valuation allowance | 1,829,030 | 1,784,880 | ||||||
Total deferred | - | - | ||||||
Total provision for income taxes | $ | - | $ | - |
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
Schedule of Deferred Tax Assets and Liabilities
2023 | 2022 | |||||||
December 31, | ||||||||
2023 | 2022 | |||||||
Deferred tax assets | ||||||||
Net operating loss carry-forward | $ | 2,430,529 | $ | 1,061,300 | ||||
Section 174 Qualified Research Expenditures | 533,159 | 388,230 | ||||||
Stock compensation | 650,018 | 330,633 | ||||||
ROU liability | 1,291 | 91,333 | ||||||
Other | 204 | 6,120 | ||||||
Deferred tax assets, Gross | 3,615,201 | 1,877,616 | ||||||
Less: valuation allowance | (3,613,901) | (1,784,880) | ||||||
Deferred tax assets, Net | 1,291 | 92,736 | ||||||
Deferred tax liabilities | ||||||||
ROU asset | (1,291) | (92,736) | ||||||
Total net deferred tax asset | $ | - | $ | - |
- Prev
- 1
- Next